Evaluation of Quality of Care - Risk Assessment Management Programme, HA
Launched by THE UNIVERSITY OF HONG KONG · Jan 10, 2014
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with DM who are mostly independent in their activities of daily living and being followed up at GOPC regularly will be recruited.
- Exclusion Criteria:
- • Patients will be excluded if they are unable to understand or communicate in Chinese language, or refuse to give consent.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Cindy L.K. Lam, MD
Study Chair
Department of Family Medicine and Primary Care, Faculty of Medicine, The University of Hong Kong
Colman S.C. Fung, MBBS
Principal Investigator
Department of Family Medicine and Primary Care, Faculity of Medicine, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials